% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Wang:1037247,
      author       = {Wang, Justin Z and Landry, Alexander P and Raleigh, David R
                      and Sahm, Felix and Walsh, Kyle M and Goldbrunner, Roland
                      and Yefet, Leeor S and Tonn, Jörg C and Gui, Chloe and
                      Ostrom, Quinn T and Barnholtz-Sloan, Jill and Perry, Arie
                      and Ellenbogen, Yosef and Hanemann, C Oliver and Jungwirth,
                      Gerhard and Jenkinson, Michael D and Tabatabai, Ghazaleh and
                      Mathiesen, Tiit I and McDermott, Michael W and Tatagiba,
                      Marcos and la Fougère, Christian and Maas, Sybren L N and
                      Galldiks, Norbert and Albert, Nathalie L and Brastianos,
                      Priscilla K and Ehret, Felix and Minniti, Giuseppe and
                      Lamszus, Katrin and Ricklefs, Franz L and Schittenhelm, Jens
                      and Drummond, Katharine J and Dunn, Ian F and Pathmanaban,
                      Omar N and Cohen-Gadol, Aaron A and Sulman, Erik P and
                      Tabouret, Emeline and Le Rhun, Emelie and Mawrin, Christian
                      and Moliterno, Jennifer and Weller, Michael and Bi, Wenya
                      and Gao, Andrew and Yip, Stephen and Niyazi, Maximilian and
                      Aldape, Kenneth and Wen, Patrick Y and Short, Susan and
                      Preusser, Matthias and Nassiri, Farshad and Zadeh, Gelareh},
      title        = {{M}eningioma: {I}nternational {C}onsortium on {M}eningiomas
                      consensus review on scientific advances and treatment
                      paradigms for clinicians, researchers, and patients},
      journal      = {Neuro-Oncology},
      volume       = {26},
      number       = {10},
      issn         = {1522-8517},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {FZJ-2025-00580},
      pages        = {1742 - 1780},
      year         = {2024},
      abstract     = {Meningiomas are the most common primary intracranial tumors
                      in adults and are increasing in incidence due to the aging
                      population and increased access to neuroimaging. While most
                      exhibit nonmalignant behavior, a subset of meningiomas are
                      biologically aggressive and are associated with treatment
                      resistance, resulting in significant neurologic morbidity
                      and even mortality. In recent years, meaningful advances in
                      our understanding of the biology of these tumors have led to
                      the incorporation of molecular biomarkers into their grading
                      and prognostication. However, unlike other central nervous
                      system (CNS) tumors, a unified molecular taxonomy for
                      meningiomas has not yet been established and remains an
                      overarching goal of the Consortium to Inform Molecular and
                      Practical Approaches to CNS Tumor Taxonomy-Not Official
                      World Health Organization (cIMPACT-NOW) working group.
                      Additionally, clinical equipoise still remains on how
                      specific meningioma cases and patient populations should be
                      optimally managed. To address these existing gaps, members
                      of the International Consortium on Meningiomas including
                      field-leading experts, have prepared this comprehensive
                      consensus narrative review directed toward clinicians,
                      researchers, and patients. Included in this manuscript are
                      detailed overviews of proposed molecular classifications,
                      novel biomarkers, contemporary treatment strategies, trials
                      on systemic therapies, health-related quality-of-life
                      studies, and management strategies for unique meningioma
                      patient populations. In each section, we discuss the current
                      state of knowledge as well as ongoing clinical and research
                      challenges to road map future directions for further
                      investigation.Keywords: extra-axial; meningioma;
                      methylation; molecular; neurofibromatosis 2; nonmalignant;
                      radiotherapy.},
      cin          = {INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406},
      pnm          = {5252 - Brain Dysfunction and Plasticity (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5252},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {38695575},
      UT           = {WOS:001269694700001},
      doi          = {10.1093/neuonc/noae082},
      url          = {https://juser.fz-juelich.de/record/1037247},
}